Status:
UNKNOWN
Alteplase for Treatment of Empyema and Complicated Parapneumonic Effusion
Lead Sponsor:
O'Brien, Jeana D., MD, FACP, FCCP
Collaborating Sponsors:
Genentech, Inc.
Scott and White Hospital & Clinic
Conditions:
Empyema
Pleural Effusion
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to assess the benefit to patients with empyema or complicated parapneumonic effusion (CPE) using a daily versus twice daily Alteplase regimen of two different dose strateg...
Detailed Description
This is a randomized, double-blind, placebo-controlled pilot study. Patients with empyema and complicated parapneumonic effusion who are felt to require fibrinolytic therapy will be considered for stu...
Eligibility Criteria
Inclusion
- Ability to provide written informed consent
- Age greater or equal to 18 yrs
- Presence of empyema or CPE
Exclusion
- Active internal bleeding
- Pregnancy
- Prior enrollment in this study
- Platelet count less than 100,000/mm3
- Use of warfarin sodium if INR is greater than 1.7
- Use of heparin unless the PTT is less than 1.5 times baseline normal
- Known neurological disorders
- Current or pre-existing bleeding dyscrasia
- Known allergy to Alteplase
Key Trial Info
Start Date :
October 1 2004
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT00103766
Start Date
October 1 2004
Last Update
August 1 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Scott and White Memorial Hospital & Clinic
Temple, Texas, United States, 76508